Copyright
©The Author(s) 2025.
World J Clin Oncol. May 24, 2025; 16(5): 101378
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.101378
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.101378
Table 1 Baseline patient and tumor characteristics
Characteristics | Median (range) | n | % |
Sex | |||
Man | 41 | 87.2 | |
Woman | 6 | 12.8 | |
Age, years, | 61 (36-86) | ||
Location of tumor | |||
Upper | 11 | 23.4 | |
Middle | 17 | 36.2 | |
Lower | 19 | 40.4 | |
Tumor classification | |||
T3 | 18 | 38.3 | |
T4A | 7 | 14.9 | |
T4B | 22 | 46.8 | |
Lymph node status | |||
N0 | 2 | 4.3 | |
N1 | 24 | 51.1 | |
N2 | 21 | 44.7 | |
Disease stage | |||
IIIa | 5 | 10.6 | |
IIIb | 13 | 27.7 | |
IIIc | 29 | 61.7 | |
TP chemotherapy | |||
0 | 18 | 38.3 | |
1 | 4 | 8.5 | |
2 | 12 | 25.5 | |
4 | 13 | 27.7 |
Table 2 Summary of dose, fraction and IV grade esophageal toxicity
Dose level (Gy per fraction) | Number of fractions | BED (α/β), 10 | EQD2 (α/β), 10 | EQD2 (α/β), 15 | EQD2 (α/β), 3 | Number of patients | Toxicity IV grade | Time, months |
3.6 | 15 | 73.44 | 61.20 | 59.08 | 71.28 | 1.00 | ||
3.5 | 20 | 94.50 | 78.75 | 76.18 | 91.00 | 1.00 | ||
3.3 | 20 | 87.78 | 73.15 | 71.05 | 83.16 | 1.00 | ||
3.2 | 20 | 84.48 | 70.40 | 68.52 | 79.36 | 3.00 | B | 5 |
3 | 25 | 97.50 | 81.25 | 79.41 | 90.00 | 1.00 | B | 6 |
3 | 23 | 89.70 | 74.75 | 73.06 | 82.80 | 1.00 | ||
3 | 22 | 85.80 | 71.50 | 69.88 | 79.20 | 1.00 | ||
3 | 20 | 78.00 | 65.00 | 63.53 | 72.00 | 2.00 | A | 6 |
2.8 | 27 | 96.77 | 80.64 | 79.16 | 87.70 | 1.00 | A | 5 |
2.8 | 20 | 71.68 | 59.73 | 58.64 | 64.96 | 1.00 | ||
2.7 | 27 | 92.58 | 77.15 | 75.90 | 83.11 | 1.00 | B | 3 |
2.7 | 25 | 85.73 | 71.44 | 70.28 | 76.95 | 1.00 | ||
2.5 | 27 | 84.38 | 70.31 | 69.49 | 74.25 | 2.00 | a: A; b: A | a: at 4th RT; b: 10 |
2.5 | 25 | 78.13 | 65.10 | 64.34 | 68.75 | 2.00 | ||
2.5 | 20 | 62.50 | 52.08 | 51.47 | 55.00 | 1.00 | ||
2.5 | 18 | 56.25 | 46.88 | 46.32 | 49.50 | 1.00 | ||
2.4 | 28 | 83.33 | 69.44 | 68.78 | 72.58 | 1.00 | ||
2.4 | 26 | 77.38 | 64.48 | 63.87 | 67.39 | 1.00 | ||
2.4 | 25 | 74.40 | 62.00 | 61.41 | 64.80 | 3.00 | ||
2.4 | 20 | 59.52 | 49.60 | 49.13 | 51.84 | 1.00 | B | 2 |
2.3 | 28 | 79.21 | 66.01 | 65.54 | 68.26 | 1.00 | ||
2.3 | 27 | 76.38 | 63.65 | 63.20 | 65.83 | 1.00 | ||
2.3 | 26 | 73.55 | 61.30 | 60.86 | 63.39 | 2.00 | ||
2.3 | 25 | 70.73 | 58.94 | 58.51 | 60.95 | 2.00 | B | 7 |
2.3 | 23 | 65.07 | 54.22 | 53.83 | 56.07 | 1.00 | ||
2.2 | 28 | 75.15 | 62.63 | 62.32 | 64.06 | 2.00 | ||
2.2 | 25 | 67.10 | 55.92 | 55.65 | 57.20 | 2.00 | ||
2 | 30 | 72.00 | 60.00 | 60.00 | 60.00 | 2.00 | ||
2 | 27 | 64.80 | 54.00 | 54.00 | 54.00 | 2.00 | B | 7 |
2 | 25 | 60.00 | 50.00 | 50.00 | 50.00 | 5.00 |
Table 3 Ordinal logistic regression of esophageal toxicity
Estimate | SE | Wald | P value | 95%CI | |
Dose level (Gy per fraction) | -0.96 | 1.14 | 0.70 | 0.40 | -3.20 to 1.28 |
EQD2 (α/β = 10) | 0.17 | 0.06 | 6.99 | 0.01 | 0.04 to 0.29 |
Tumor classification | -0.12 | 0.37 | 0.11 | 0.74 | -0.86 to 0.61 |
- Citation: Zhang SM, Sun J, Pan XO, Zhu WC, Zhou YK. Toxicity of dose-escalated, hypofractionated helical tomotherapy for inoperable thoracic esophageal squamous cell carcinoma. World J Clin Oncol 2025; 16(5): 101378
- URL: https://www.wjgnet.com/2218-4333/full/v16/i5/101378.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i5.101378